Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 1,100
- Avg volume
- 22,130
- Day's range
- $0.08 – $0.08
- Shares out
- —
- Stochastic %K
- 64%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplas...
Show more
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 403 770 2469
- Website
- https://marvelbiotechnology.com
- Address
- 505 8th Avenue S.W., Suit 420, Calgary, Canada
Latest news
No headlines yet.
Stocktwits
AlanBoyd123
Oct 25, 5:29 PM
$MBCOF CEO.CA just featured Marvel's leadership in an Inside the Boardroom segment. That's a pretty visible platform for early-stage biotech. MB-204 moving toward first-in-human with CMAX locked in as the Phase I site adds to the momentum here
0 replies
EmielTheBlessed
Oct 23, 5:29 PM
$MBCOF most biotech companies in the autism space are working with existing drug classes. MB-204 is pushing toward first-in-human testing with no approved drug currently doing what it's designed to do, which is a pretty distinct position for an early-stage candidate
0 replies
Nolder
Oct 21, 5:29 PM
$MBCOF first-in-human testing for MB-204 is a real step forward in the oncology drug dev pipeline. A lot of biotech companies are pushing into this space right now and CMAX as the Phase I site is a solid choice. This week's news puts them in line with where early-stage clinical activity is heating up
0 replies
newsfile_corp
Oct 21, 4:39 PM
https://nfne.ws/320161
$MBCOF $MRVL.TSXV @ceodotca #Banking #FinancialServices #JuniorMining #Mining #MiningStocks #Technology #Lead #Metal
TheGoodestBoy
Oct 19, 5:29 PM
$MBCOF Interesting. Phase I trials in oncology can open the door to some pretty significant patient populations depending on the indication. CMAX was selected as the clinical site, which suggests they're moving MB-204 through a fairly structured development path
0 replies
newsfile_corp
Sep 1, 9:02 PM
https://nfne.ws/312429
$MBCOF $MRVL.TSXV @marvel #Chemicals #Biotechnology #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
newsfile_corp
May 20, 11:01 AM
https://nfne.ws/298109
$MBCOF $MRVL.TSXV @marvelbiotechnology #Chemicals #Biotechnology #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Inves
newsfile_corp
Apr 17, 8:31 PM
https://nfne.ws/293094
$MBCOF $MRVL.TSXV @marvelbiotechnology #Chemicals #Biotechnology #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Inves
